Priority 21 from the Mesothelioma PSP
| UNCERTAINTY: What is the current best method (e.g. contrast enhanced MRI vs PET) to accurately assess disease progression in mesothelioma patients? (JLA PSP Priority 21) | |
|---|---|
| Overall ranking | 21 |
| JLA question ID | 0025/21 |
| Explanatory note | Not available for this PSP |
| Evidence | No systematic reviews or studies identified |
| Health Research Classification System category | Cancer |
| Extra information provided by this PSP | |
|---|---|
| Original uncertainty examples | How do you accurately assess disease progression? |
| Comparison | None identified |
| Submitted by | Health Professional |
| Outcomes to be measured | Detection of progression |
| PSP information | |
|---|---|
| PSP unique ID | 0025 |
| PSP name | Mesothelioma |
| Total number of uncertainties identified by this PSP. | 53 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | 16 December 2014 |